Catalyst Event

Sanofi (SNY) · Other

From KEDI Nvidia Fixed Tech100 Index (KNVDT100)

3/23/2026, 12:00:00 AM

OtherSentiment: Positive

Sanofi entered a licensing agreement with Kali Therapeutics for its autoimmune drug candidate KT501, involving $180 million in near-term payments and up to $1.05 billion in milestones.

Korean Translation

사노피, 칼리 테라퓨틱스와 자가면역질환 후보물질 KT501에 대한 라이선스 계약 체결. 계약금 1억 8천만 달러 및 마일스톤 최대 10억 5천만 달러 포함.

Related Recent Events

View Full Timeline